Consumer robot company iRobot Corp. (Nasdaq: IRBT) is set to report its first quarter 2019 earnings results Tuesday after market closes. Analysts view the company’s earnings to decline 17% year-over-year to $0.59 per share and revenue to grow 16% to $251.4 million. iRobot stock slid about 1.5% during the midday hours on Monday and ended down 0.7% at $128.73.
iRobot sells its products directly to consumers through on-line stores and indirectly through resellers and distributors. For the last reported quarter, iRobot’s revenue grew 18% annually to $384.7 million. Earnings jumped to $0.88 per share in Q4 from $0.16 per share in the fourth quarter of 2017.
Historically, iRobot had experienced higher revenue in the second half of the year compared to the first half of the year because of seasonal holiday demand. This quarter, investors will be keenly watching on the new product updates from the company and its actions to mitigate the effect of the US/Chinese trade war.
For the fiscal year ended December 29, 2018, sales to non-US customers accounted for 48.7% of total revenue. The Bedford, Massachusetts-based firm outsources its manufacturing of the consumer products to three contract manufacturers, each of which manufactures the robots at a single plant in Southern China.
The ongoing trade war between the US and China has been a major concern for iRobot. The additional 25% tariff on certain goods imported from China has been delayed so far and there have been negotiations going on in this regard between the US and Chinese governments. To mitigate this impact, the company said in Q4 earnings call that one of its contract manufacturers plans to begin partial production outside of China beginning in 2019.
For 2019, iRobot expects revenue to be in the range of $1.28 billion to $1.31 billion, representing a year-over-year growth of 17% to 20%, and EPS of $3.00 to $3.25, excluding discrete items.
iRobot stock, which hit a 52-week high ($132.88) on early March, had gained 54% since the beginning of 2019 and more than doubled in the past 12 months.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on